[HTML][HTML] Discontinuation risk comparison among 'real-world'newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
GYH Lip, X Pan, S Kamble, H Kawabata, J Mardekian… - PLoS …, 2018 - journals.plos.org
Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation …
patients to an increased risk of stroke. This study describes the real-world discontinuation …
Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta‐analysis of subgroups
A Gómez-Outes, AI Terleira-Fernández… - …, 2013 - Wiley Online Library
Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …
[HTML][HTML] Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias …
T Morimoto, B Crawford, K Wada, S Ueda - Journal of Cardiology, 2015 - Elsevier
Background This study was designed to compare efficacy and safety among novel oral
anticoagulants (NOACs), which have not been directly compared in randomized control …
anticoagulants (NOACs), which have not been directly compared in randomized control …
Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation
Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …
Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation
MA Mamas, S Batson, KG Pollock, S Grundy… - The American Journal of …, 2022 - Elsevier
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
Prescription patterns and outcomes of patients with atrial fibrillation treated with direct oral anticoagulants and warfarin: a real-world analysis
Background: Direct oral anticoagulants (DOACs) have been found to be similar or superior
to warfarin in reducing ischemic stroke and intracranial hemorrhage (ICH) in patients with …
to warfarin in reducing ischemic stroke and intracranial hemorrhage (ICH) in patients with …
Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient …
CI Coleman, WF Peacock, TJ Bunz, MJ Alberts - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …
[HTML][HTML] On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects
D Hutto, GCM Siontis, PA Noseworthy… - IJC Heart & Vasculature, 2022 - Elsevier
Background Numerous observational studies support the safety and effectiveness of the
direct oral anticoagulants (DOAC) for stroke prevention in atrial fibrillation (AF), but these …
direct oral anticoagulants (DOAC) for stroke prevention in atrial fibrillation (AF), but these …